Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach

Nonalcoholic steatohepatitis (NASH) might soon become the leading cause of end-stage liver disease and indication for liver transplantation worldwide. Fibrosis severity is the only histological predictor of liver-related morbidity and mortality in NASH identified to date. Moreover, fibrosis regressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Brennan, Paul N., Elsharkawy, Ahmed M., Kendall, Timothy J., Loomba, Rohit, Mann, Derek A., Fallowfield, Jonathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236408/
https://www.ncbi.nlm.nih.gov/pubmed/37268740
http://dx.doi.org/10.1038/s41575-023-00796-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236408/
https://www.ncbi.nlm.nih.gov/pubmed/37268740
http://dx.doi.org/10.1038/s41575-023-00796-x

Ejemplares similares